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Abstract 
 
In the outpatient setting, Glucagon-like peptide-1 (GLP-1) receptor agonists have proved to 
be highly efficacious drugs that provide glycaemic control with a low risk of hypoglycaemia.  
These characteristics make GLP-1 receptor agonists attractive agents to treat dysglycaemia in 
perioperative or high-dependency hospital settings; where glycaemic variability and 
hyperglycaemia are associated with poor prognosis. GLP-1 also has a direct action on the 
myocardium and vasculature  - which may be advantageous in the immediate aftermath of a 
vascular insult. This is a narrative review of the work in this area.  
The aim was to determine the populations of hospitalised patients being evaluated and the 
clinical and mechanistic end-points tested, with the institution of GLP-1 therapy in hospital. 
We searched the PubMed, Embase, and Google scholar databases, combining the term 
‘glucagon-like peptide 1’ OR ‘GLP-1’ OR ‘incretin’ OR ‘liraglutide’ OR ‘exenatide’ OR 
‘lixisenatide’ OR ‘dulaglutide’ OR ‘albiglutide’ AND ‘inpatient’ OR ‘hospital’ OR 
‘perioperative’ OR ‘postoperative’ OR ‘surgery’ OR ‘myocardial infarction’ OR ‘stroke’ OR 
‘cerebrovascular disease’ OR ‘transient ischaemic attack’ OR ‘ICU’ OR ‘critical care’ OR 
‘critical illness’ OR ‘CCU’ OR ‘coronary care unit’. 
Pilot studies were reported in the fields of acute stroke, cardiac resuscitation, coronary care 
and perioperative care that showed advantages for GLP-1 therapy; with normalisation of 
glucose, lower glucose variability and lower risk of hypoglycaemia. Animal and human 
studies have reported improvements in myocardial performance when given acutely after 
vascular insult or surgery, but these have yet to be translated into randomised clinical trials. 
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INTRODUCTION 
In the outpatient setting, GLP-1 receptor agonists (GLP-1 RA) are considered to provide 
effective glycaemic control, weight loss and cardiovascular benefits with a low risk of 
hypoglycaemia 1 2. The use of GLP-1 RA have increased rapidly and are now recommended 
for use as second-line therapy for Type 2 Diabetes (T2DM) 3. As a result, individuals treated 
with GLP-1 RA will be more frequently encountered at the in-patient setting. Existing 
clinical guidelines for inpatient diabetes control only briefly discuss their role, if at all 4-6. 
Furthermore, the therapeutic benefit for GLP-1 RA is being tested in a range of acute clinical 
settings including perioperative, coronary care and critical care 7-15. This narrative review will 
outline the inpatient clinical areas in which GLP-1 RA are being tested, the panoply of 
actions of GLP-1 that offer the potential for benefit in acute illness, and the outcome 
measures reported so far.  This review will not encompass the effectiveness for GLP-1 RA to 
reduce hospitalisation or mortality from macrovascular disease (such as heart failure) which 
has been covered extensively elsewhere 16 17; nor will it assess the usefulness of initiating 
GLP-1 RA therapy in the months before surgery. GLP-1 RA have been used with some 
success for short-bowel syndrome 18 but our analysis is restricted to the use of GLP-1 for 
acute illness, perioperative and critical care areas. 
 
Search methodology 
We conducted a comprehensive search in the English-language literature to identify all 
relevant studies, regardless of publication status or year of publication. We searched the 
PubMed, Embase, and Google scholar databases, combining the term ‘glucagon-like peptide 
1’ OR ‘GLP-1’ OR ‘incretin’ OR ‘liraglutide’ OR ‘exenatide’ OR ‘lixisenatide’ OR 
‘dulaglutide’ OR ‘albiglutide’ AND ‘inpatient’ OR ‘hospital’ OR ‘perioperative’ OR 
‘postoperative’ OR ‘surgery’ OR ‘myocardial infarction’ OR ‘stroke’ OR ‘cerebrovascular 
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disease’ OR ‘transient ischaemic attack’ OR ‘ICU’ OR ‘critical care’ OR ‘critical illness’ OR 
‘CCU’ OR ‘coronary care unit’. Studies could include early or late phase human trials and 
those using animal models. We searched the National Institutes of Health database 
(http://clinicaltrials.gov/) and the EU clinical trials register (www.clinicaltrialsregister.eu) for 
ongoing and unpublished trials. We applied backward and forward snowballing to identify 
further papers. The bibliographies of all included studies and pertinent reviews were scanned 
for additional references. If required, the corresponding author of an included study was 
contacted for information regarding unpublished trials or complementary information on their 
own trial(s). The last search was performed in August 2018. 
 
Stroke and brain injury 
GLP-1 RAs have certain properties that lend themselves to use in cerebrovascular disease: 
most obvious is the ability to normalise glucose with a low propensity to hypoglycaemia. 
Ischaemic stroke leads to a penumbra of neural tissue that is potentially salvageable. 
Hyperglycaemia is associated with worse clinical outcomes in stroke including: haemorrhagic 
transformation, extent of neurological disability and death 19 20. Of those presenting with 
ischaemic stroke, 30% have known diabetes, 20% are newly recognised to have diabetes and 
a further 30% have impaired fasting glucose or glucose tolerance 21-23. Therefore just 20% 
have normal glucose homeostasis. Significant consequences arise from dysglycaemia: this 
may be due to the production of the excitatory neurotransmitter glutamate, or to reactive 
oxygen species which adversely affect the ischaemic penumbra. However, clinical trials in 
acute stroke have failed to show a clinical benefit from the amelioration of hyperglycaemia 
with insulin in the first 24-48 hours 24-27. Neurological gains from the avoidance of 
hyperglycaemia are mitigated by hypoglycaemia from the use of insulin. Hypoglycaemia is 
associated with increased markers of cerebral cellular distress including: elevated glutamate: 
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lactate/pyruvate ratio: and glycerol - which may themselves contribute to disability and death 
28-31. There is therefore a J-shaped association between plasma glucose and outcome after 
stroke 32. GLP-1 RA offer the possibility of normalising glucose without hypoglycaemia.  
In a pilot study of 11 patients with acute ischaemic stroke, subcutaneous exenatide (for a 
median of six-days) restricted the incidence of hyperglycaemia (> 8.6mmol/L) to less than 
5%, with no hypoglycaemia. Of note, nausea and vomiting occurred in half the cohort 7, 
which may prove to be a limiting factor in future studies. A large phase 2 trial is underway: 
the Trial of Exenatide in Acute Ischaemic Stroke (TEXAIS) is a three year, multi-centre, 
open label randomised controlled trial (RCT) comparing exenatide to standard care. It aims to 
recruit 528 patients with a clinically meaningful primary end-point of major neurological 
improvement at seven days 13.  
Exendin-4 is a 39 amino acid peptide originally isolated from the oral secretions of the Gila 
monster lizard.  It shares 53% sequence homology with GLP-1 and has been used in a 
number of pre-clinical studies 33. Murine studies of ischaemic brain damage using Exendin-4 
34 and liraglutide 35 show that they are capable of crossing the blood-brain barrier to act 
directly on the brain to produce neuroprotective and anti-inflammatory effects 36 37. The 
neuroprotective properties that GLP-1 RAs have shown in animal studies has also led to their 
evaluation in patients with brain injury after cardiac arrest. A dual-centre study in Denmark 
has investigated the neuroprotective effects of exenatide administered within four hours of 
the return of spontaneous circulation to comatose patients resuscitated from out-of-hospital 
cardiac arrest 14. The efficacy endpoint was the area under curve (AUC) from 0 to 72 hours 
after admission of neuron-specific enolase – a predictor of outcomes after cardiac arrest 38. 
Although exenatide was effective in normalising blood glucose (median blood glucose eight 
hours after admission was 5.8 mmol/L vs 7.3 mmol/L, in placebo; P<0.0001), exenatide did 
not reduce neuron-specific enolase levels and did not significantly improve a composite end-
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point of death and poor neurological function after 180 days 14. Of note, exenatide was not 
administered until after the return of spontaneous circulation which could limit the 
effectiveness. More recently, a six-hour infusion of either 17.4 μg of exenatide or placebo, 
within four hours from sustained return of spontaneous circulation, showed that exenatide 
lowered glucose and increased the clearance of lactate (a surrogate marker for adequate tissue 
perfusion39) by 21% more than placebo 15. 
 
Myocardial infarction 
Over 20 years after the ‘Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial 
Infarction’ (DIGAMI) study, evidence for the necessity of tight glycaemic control in the 
immediate aftermath of AMI remains debatable 40. The DIGAMI study was primarily a trial 
of glucose-insulin-potassium (GIK) rather than glycaemic control and was predicated by the 
ideas that GIK may ameliorate platelet aggregation, reduce transmembrane excitability and 
therefore arrhythmias, and facilitate a switch in myocardial metabolism away from oxygen-
dependent fatty acid metabolism to carbohydrate metabolism. After the study, it could not be 
determined whether mortality benefit at one year was due to the immediate intravenous 
infusion of GIK, subsequent subcutaneous insulin, or both. It was hoped that the follow-up 
DIGAMI2 would answer this but unfortunately was underpowered, in part due to protocol 
violations between groups and advances in therapeutic use of aspirin and statins 41. This 
results in a quandary as to glycaemic management after AMI. However, GLP-1 RA have 
properties, in addition to glucose lowering, that make them attractive for use in the immediate 
aftermath of AMI. The GLP-1 receptor is expressed in the heart 42, and exendin-4 directly 
activates cardiomyocyte signalling pathways 43 which raises the possibility they may act 
directly on the cardiac muscle to improve ventricular ejection fraction and cardiac index 16. 
GLP-1 RA may also have an effect on increasing myocardial reliance on glucose, rather than 
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fatty acid metabolism (thereby being more oxygen efficient), akin to that proposed for GIK, 
although this theory is contentious 44-47. Altered myocardial metabolism has been reported 
with albiglutide. In a murine model, albiglutide reduced the myocardial infarct size in 
association with increased cardiac uptake and utilisation of glucose. Gene expression analysis 
indicated an upregulation of key glucose metabolism genes in the preserved myocardium post 
treatment 48.  
 
Intriguingly, GLP-1 RA has a direct effect on myocytes independent to its action via the 
GLP-1 receptor. Studies of isolated cardiomyocytes, from GLP-1 receptor knockout mice, 
have shown a robust response to lixisenatide on the contractility response 49. Within the 
coronary vessels themselves, human recombinant GLP-1 (7–36) amide - the cleavage product 
of GLP-1 (1-36) - exerts a beneficial effect on endothelial function 50 51. In coronary 
endothelial cells taken from subjects with T2D, Exendin-4 could augment endothelial nitric 
oxide synthase (eNOS) phosphorylation and nitric oxide (NO) production 52 – pathways that 
are known to lead to vascular relaxation 53. Glucagon-like peptide 1 [7-36 amide]54 and 
liraglutide55 can exert a protective effect against endothelial dysfunction induced by 
hyperglycaemia and/or inflammation through a reduction of tumour necrosis factor-α (TNF-
α)-induced nuclear factor-κB activation. This can decrease inflammatory gene expression, 
including vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 56. 
These properties have made GLP-1 RAs an attractive treatment option for patients with acute 
coronary ischaemia, as was suggested from a number of animal models 57-60. In ten human 
subjects with left ventricular (LV) dysfunction, a 72-h infusion of GLP-1 (7–36) amide (1.5 
pmol/kg/min), commenced after primary coronary angioplasty for acute myocardial 
infarction resulted in improved global and regional LV wall motion scores and reduced 
hospital stay (6.1 ± 1.3 days) vs 9.8 ± 1.5 days in controls 61. There followed three 
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publications by a group in Copenhagen, from a larger RCT (n=172) comprised of patients 
with ST elevation myocardial infarction (STEMI) treated with exenatide 9-11, both with and 
without diabetes. Improvements in infarct size were seen, but no mortality benefit, when 
administered intravenously during primary percutaneous coronary intervention (PCI) 9 10. 
Since then, most 11 62-64, but not all 65 trials have reported an effect of reducing coronary 
infarct size. Differences in glycaemic control achieved by the intervention may go towards 
explaining the difference. The protocol used by the Copenhagen group 9-11 comprised 
exenatide or placebo given intravenously 15 min prior to intervention and continued six hours 
post-PCI – at which time blood glucose was 8.0 mmol/L in controls and 6.3 mmol/L with 
exenatide. Conversely in a study by Roos et al 65 66, exenatide was administered for 72-hours 
after primary angioplasty in 91 individuals, with blood glucose measured every three-hours 
on day one, reduced to four-times per day thereafter; there were no differences in the number 
of hypoglycaemic episodes (considered <4 mmol/L [10 events in exenatide vs 9 in placebo; 
P=0.530]) or hyperglycaemic episodes (considered >10 mmol/L [3 events in exenatide vs 10 
in placebo; P=0.064]). 
The use of GLP-1 RA in non-ST elevation myocardial infarction (nSTEMI) was examined in 
a study of 90 patients randomized to liraglutide (0.6 mg for two days, 1.2 mg for two days, 
followed by 1.8 mg for three days) or placebo for seven days, liraglutide improved left 
ventricular ejection fraction by 4.7% more than placebo after three-months 67. However, this 
seems a modest improvement and may not translate into measurable clinical outcomes. A 
significant improvement has been defined as an increase in the ejection fraction of ≥8% 
(which is two times the inter-observer variability with echocardiography) 68. 
Is it feasible to achieve rapid normalisation of glucose after myocardial infarction with GLP-
1? This was addressed in a study of 40 patients admitted to a CCU with hyperglycaemia 
ranging from 7.8 to 22.2 mmol/L 69. Patients received intravenous exenatide as a bolus 
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followed by a fixed dose infusion for up to 48 hours.  Exenatide effectiveness was 
benchmarked to historical controls treated with insulin infusions. There was no difference in 
performance in the attainment of a target glucose range of 5.6-7.8 mmol/L although exenatide 
was discontinued in three patients after failure to achieve glycaemic control. Control was 
achieved without any episodes of severe hypoglycaemia (<2.8 mmol/L) although nausea 
(occurring in 16 patients) was problematic. By far the largest trial to date has been the 
Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) study 70. This randomised 
6068 patients within 180 days of a cardiovascular event that required hospitalization. Once-
daily subcutaneous injection of 20 mcg lixisenatide, as an add-on therapy to background 
antidiabetic medications, for 25 months was non-inferior to placebo for the composite 
occurrence of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for unstable 
angina or heart failure, and revascularization. This study provided data for cardiovascular 
safety of lixisenatide but no advantage. The six-month window from cardiovascular event to 
recruitment does however, make it distinct from the trials described.  
 
Cardiac surgery 
Peri-operative glucose control reduces the incidence of sepsis and mediastinitis after 
cardiothoracic surgery 71 72. Van den Berghe’s 2001 paper 73, reporting improved post-
operative outcomes with tight glycaemic control after (predominantly cardiovascular) 
surgery, continues to be hotly debated as the findings have not been replicated in multicentre 
trials 74-77. There is an increased likelihood of hypoglycaemia from the intensification of 
glucose targets with insulin therapy, which leads to worse outcomes 74 76 78. GLP -1 therapy 
offers the prospect of glycaemic control with less likelihood of hypoglycaemia after coronary 
surgery which may tip the balance in favour of tighter glycaemia targets when using this 
drug. The perioperative administration of exenatide (1.2-1.5 pmol/kg/min) has proved to be 
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effective at improving glucose levels in patients with diabetes and stress hyperglycaemia 
undergoing cardiac surgery and can reduce peri-operative insulin requirements 79-81, although 
reduction in hypoglycaemia was not always observed 80. One trial in subjects with type 2 
diabetes used a much higher infusion rate (3.6 pmol/kg/min) for 12 hours after transfer from 
the operating room to the intensive care unit (ICU) 82 combined with insulin as a rescue 
medication if glucose concentrations were >7.8 mmol/L, for over three hours. The AUC for 
plasma glucose was no different between controls (receiving insulin alone) and exenatide. 
Compared to patients receiving intravenous insulin, a lesser insulin requirement, with fewer 
dose adjustments, was necessary in the GLP-1 group over the first six hours. 
 
In a small study of 20 patients with coronary heart disease and preserved left ventricular 
function who underwent CABG, use of GLP-1 [7-36 amide]  as a continuous infusion 
beginning 12 hours before CABG and continuing for 48 hours resulted in less requirement for 
inotropic support– even in patients without diabetes 83. However, no improvement in 
echocardiographic features of left ventricular dysfunction was seen in this study, or in a 
similarly executed study of perioperative intravenous exenatide with cardiothoracic surgery 81 
83. These postoperative trial outcomes corroborate the findings post MI suggesting little role 
for exogenous GLP-1 to improve cardiac performance acutely.   
The ‘GLP-1 for bridging of hyperglycaemia during cardiac surgery’ (GLOBE) study is a 
large randomised parallel placebo-controlled trial, currently underway, with the intention of 
recruiting 274 patients undergoing cardiac surgery, with or without diabetes mellitus 84. 
Patients will receive 0.6 mg liraglutide or placebo the evening before; and 1.2 mg liraglutide 
or placebo just prior to surgery. The primary endpoint is intra-operative insulin requirement: 
a relevant outcome as greater insulin infusion rates are associated with adverse clinical 
sequelae 73 85. Taken together, these studies suggest that peri-operative GLP-1 helps to 
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achieve glycaemic control, with a lessened requirement for insulin. Further evidence is 
required whether this translates into fewer hypoglycaemic episodes. The immediate 
haemodynamic benefits are unproven. 
 
General surgery 
Less work has been undertaken in non-cardiac surgery. In a proof-of-concept study, eight 
patients with type 2 diabetes who had undergone major surgical procedures, were studied 
with a cross-over design, between the second and the eighth postoperative day 86.  Patients 
received intravenous GLP-1 (7–36) amide (1.2 pmol/kg/min) or placebo over eight hours, 
each administered in randomized order in the fasting state. From a fasting glucose of 
10mmol/L, infusion of GLP-1, lowered plasma glucose concentration to target (<7mmol/L) 
within 150 mins, whereas glucose remained above target throughout the 8-hour placebo 
infusion (P <0.001). Rapid attainment of normoglycaemia in the postoperative period makes 
GLP-1 an attractive option.  Data are needed as to the efficacy of simple subcutaneous 
regimes. 
For patients undergoing hip surgery, perioperative hyperglycaemia is associated with 
coagulation activation and an increased risk of venous thromboembolism 87. The effect of 
liraglutide on markers of coagulation has been tested in obese adults without diabetes, over 
the first three days after hip surgery. Despite improvement in median glucose (5.5mmol/L vs. 
5.8 mmol/L with placebo; P = 0.04) there was negligible change in the markers of 
coagulation activation 88.  Overall, there are few data to support the specific indication of 
GLP-1 RA use with general surgery. 
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Intensive care unit 
The challenge of maintaining blood glucose between the hazards of hyper- and 
hypoglycaemia is equally true in ICU as it is with peri-operative patients. Tight glycaemic 
control (4.4-6.1mmol/L) significantly increases the risk for hypoglycaemia, which can lead to 
poor outcomes 74 76. The administration of GLP-1 (7–36) amide has been tested for its 
glucopaenic action at the time of ICU admission. In a parallel-design RCT, 72-hr infusion of 
GLP-1 did not reduce intravenous insulin requirement nor the rate of hypoglycaemia 
compared to saline control, although there was less plasma glucose variability with GLP-1. 
Low glucose variability is protective in ICU patients, even when mean glucose levels are 
elevated 89, making this a potential attribute of GLP-1 therapy in the ICU environment.  
Of note, this study did not control for the routes or quantity of nutritional support 8. An open-
label RCT in India evaluated the effect of commencing fixed-dose liraglutide (1.2mg) from 
the time of ICU admission: in a study population of 120 individuals, 46 were considered to 
have pre-existing T2DM and another 53 stress-hyperglycaemia. Intravenous insulin infusion 
was also used as required. Liraglutide reduced hypoglycaemia frequency and the variation of 
capillary glucose but with no difference in mean capillary glucose 90.    An intriguing line of 
inquiry is whether GLP-1 can also ameliorate ICU catabolism. Critically ill patients in ICU 
suffer significant muscle loss. This worsens ICU mortality but also leads to debilitating 
weakness in those surviving to ICU discharge 91. Hyperglucagonaemia is thought to be a key 
factor to provoke catabolism and hyperglycaemia in critical illness 92 93. Given that a core 
attribute of GLP-1 is to suppress glucagon release from pancreatic alpha-cells 94, GLP-1 has 
theoretical anti-catabolic action as well as being effective in ameliorating stress 
hyperglycaemia 86 95.  
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A further challenge in prolonged critical illness is to maintain normoglycaemia in the setting 
of enteral and parenteral feeding protocols. A number of mechanistic studies from a group in 
Adelaide, Australia have shown that an infusion of GLP-1-(7–36) amide at 1.2 pmol/kg/min 
attenuates, but not abolishes, the glycaemic response to enteral nutrition in critically ill 
patients with stress hyperglycaemia 95 96 and with type 2 diabetes 97. Slowing of gastric 
emptying appears to contribute to the glucose-lowering effect of exogenous GLP-1 in 
critically ill patients following a 100ml intra-gastric 'meal' 96. However, delayed gastric 
emptying is common in the critically ill and may occur in up to half of all ventilated patients 
98. This may limit the magnitude of glycaemic control that could be achieved with GLP-1 RA 
during enteral feeding 96. Even so, there may be the potential for benefit even in patients fed 
parenterally. In a cross-over study of nine critically ill patients fed with parenteral nutrition 
consisting of glucose (3.2 ± 1.4 mg/kg/min), amino acids (n=8; 0.9 ± 0.2 mg/kg/min), with or 
without lipid emulsions, four hours infusion of GLP-1-(7–36) amide lowered glucose from 
11.7 ± 1.3mmol/L (with placebo) to 8.8 ± 1.4 mmol/L (P<0.001) 99. Nausea is often 
encountered with GLP-1 RA but may be less of a concern in sedated patients receiving small 
intestinal feeding. Further issues to contend with in critical illness are kidney failure; 
pancreatitis; and the use of vasoactive drugs (including catecholamines) leading to a counter-
regulatory hormonal response. 
 
Conclusion 
GLP-1 RA have a number of properties in addition to glucose lowering, which could be 
advantageous when started in an acute, hospitalised setting. However, there are few trial data 
in human subjects to support their adoption in routine clinical practice in this environment. 
The increasing use of GLP-1 RA in outpatients will mean that patients using these 
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medications will become increasingly seen in acute settings. Trials are needed to establish 
their place in acute illness. 
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